2025年12月1日,人类首次试验四氯丁二烯(IV)聚苯乙烯(Psilocin),以治疗狂食紊乱。 Entropy Neurodynamics began the first human trial of IV psilocin for binge eating disorder on Dec. 1, 2025.

Entropy Neurodynamics已启动全球首个使用静脉注射裸盖素（TRP-8803）治疗暴食症的临床试验，并于2025年12月1日为首位患者施药。 Entropy Neurodynamics has begun the world’s first clinical trial using intravenous psilocin, in the form of TRP-8803, to treat binge eating disorder, dosing its first patient on December 1, 2025. 这项与斯温伯恩大学合作进行的试验旨在评估安全性,耐受性和潜在的疗效,提供比口服psilocybin更受控的迷幻体验. The trial, conducted with Swinburne University, aims to assess safety, tolerability, and potential efficacy, offering a more controlled psychedelic experience than oral psilocybin. 这一里程碑标志着在探索BED新治疗方法方面取得重大进展,而BED是有效药物选择有限的一个条件。 This milestone marks a significant advancement in exploring novel treatments for BED, a condition with limited effective medication options.